To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Safety and immunogenicity… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

Journal article
Authors Dang Duc Anh
Do Gia Canh
Anna Lena Lopez
Vu Dinh Thiem
Phan Thi Long
Nguyen Hong Son
Jacqueline Deen
Lorenz von Seidlein
Rodney Carbis
Seung Hyun Han
Seong Hye Shin
Stephen Attridge
Jan Holmgren
John Clemens
Published in Vaccine
Volume 25
Issue 6
Pages 1149-55
ISSN 0264-410X
Publication year 2007
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Pages 1149-55
Language en
Keywords Administration, Oral, Adolescent, Adult, Cholera, immunology, microbiology, prevention & control, Cholera Vaccines, administration & dosage, adverse effects, immunology, Double-Blind Method, Female, Humans, Male, Vaccines, Inactivated, administration & dosage, adverse effects, immunology, Vibrio cholerae O1, immunology, Vibrio cholerae O139, immunology, Vietnam
Subject categories Medical and Health Sciences


Vietnam currently produces an orally administered, bivalent (O1 and O139) killed whole-cell vaccine and is the only country in the world with endemic cholera to use an oral cholera vaccine in public health practice. In order to allow international use, the vaccine had to be reformulated to meet World Health Organization (WHO) requirements. We performed a randomized, placebo controlled, safety and immunogenicity studies of this reformulated vaccine among Vietnamese adults. One hundred and forty-four subjects received the two-dose regimen and 143 had two blood samples obtained for analysis. We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?